Showing results (21-30 of 80) with videos related to

Sort By:
Pageof 8
Annals of Hematology|May 11, 2021
Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registryHeiner Zimmermann, Mirko Nitsche, Christiane Pott, et al.
Blood|December 9, 2010
Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysisBarbara F Eichhorst, Kirsten Fischer, Anna-Maria Fink, et al.
Blood|December 8, 2005
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphomaChristiane Pott, Carsten Schrader, Stefan Gesk, et al.
Blood|October 1, 2005
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemiaMonika Brüggemann, Thorsten Raff, Thomas Flohr, et al.
Oncoimmunology|March 5, 2016
Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30Christian Kellner, Andreas Günther, Andreas Humpe, et al.
British Journal of Haematology|June 27, 2007
Trisomy 19 is associated with trisomy 12 and mutated IGHV genes in B-chronic lymphocytic leukaemiaLudger Sellmann, Stefan Gesk, Christoph Walter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2022
Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and VenetoclaxMoritz Fürstenau, Jonathan Weiss, Adam Giza, et al.
Cancers|October 14, 2022
CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression AnalysisAnke Schilhabel, Peter Jonas Walter, Paula Cramer, et al.
European Journal of Haematology|November 19, 2016
Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trialOthman Al-Sawaf, Kirsten Fischer, Carmen D Herling, et al.
Blood|December 20, 2017
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLLNatalie Dimier, Paul Delmar, Carol Ward, et al.
Pageof 8